Janux Therapeutics Inc (JANX) AI Stock Analysis

• Market Cap: $1.47B
• Dividend Yield: N/A
• Average Volume (3M): 1.04M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.93
• Revenue Growth: 28.12%
• EPS Growth: -11.01%
• Country: US
• Employees: 91
• Sector: Healthcare
• Sector Strength: 55
• Industry: Biotechnology
• EPS (TTM): -0.38
• Shares Outstanding: 59,175,156
• 10 Day Avg. Volume: 600,406
• 30 Day Avg. Volume: 1,036,787
• PEG Ratio: -0.15
• Price to Book (P/B): 1.70
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -11.06
• Enterprise Value/Market Cap: 0.35
• Enterprise Value/Revenue: 10.81
• Enterprise Value/Gross Profit: 58.89
• Enterprise Value/Ebitda: -1.46
• 1Y Price Target: $76.57
• Price Target Upside: 224.31% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 10

• Rating: 46 Neutral
• Price Target: $25.00 ▲(5.89%Upside)

Janux Therapeutics Inc shows strong revenue growth and a solid balance sheet with minimal debt, which are significant positives. However, ongoing profitability challenges and negative cash flows from operations weigh heavily on the stock's attractiveness. Technical indicators suggest a mixed outlook, with the stock trading below key moving averages despite some positive momentum signals. The valuation reflects ongoing losses, which impacts the overall score negatively.

Positive Factors

Financial Stability

Janux has more than 8 years of cash available, indicating strong financial stability to support ongoing research and development.

Product Potential

JANX007 has a compelling product profile that supports widespread adoption, including in the community.

Negative Factors

Competitive Challenges

There might be a similar safety-efficacy tradeoff with JAN007’s other safety-optimized competitor, VIR-5500, which could pose challenges.

Market Skepticism

Janux has a short interest of 19.4% of its float, suggesting skepticism in the market about the stock.

Janux Therapeutics Inc Business Overview & Revenue Model

Company Description

Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. Janux Therapeutics, Inc. is also developing a Tumor Activated Immunomodulator (TRACIr) costimulatory bispecific product candidate against programmed death-ligand 1 and CD28 designed to improve the anti-tumor activity of T cells. In addition, its EGFR-TRACTr is designed to target EGFR in many cancer types with multiple approved monoclonal antibodies. The company was incorporated in 2017 and is headquartered in La Jolla, California.

How the Company Makes Money

Janux Therapeutics Inc generates revenue primarily through strategic collaborations and partnerships with larger pharmaceutical companies. These partnerships often include upfront payments, milestone payments, and potential royalties on sales if the developed therapies receive regulatory approval and market success. Additionally, Janux may engage in licensing agreements for its proprietary technology, contributing to its revenue streams. The company invests heavily in research and development to advance its pipeline of immunotherapy candidates, which, upon successful clinical trials and regulatory approval, could lead to commercialization and direct sales revenue.

Janux Therapeutics Inc Financial Statement Overview

Summary

Janux Therapeutics Inc demonstrates strong revenue growth and a robust balance sheet with minimal debt. Despite these strengths, the company is still facing challenges with profitability and cash generation from operations, as indicated by negative net income and operating cash flows. The company remains reliant on financing to support its cash needs.

Income Statement

Janux Therapeutics Inc has shown a significant increase in revenue from $8.08 million in 2023 to $10.59 million in 2024, representing a growth rate of approximately 30.4%. However, the company continues to operate at a net loss with a net profit margin of -651.6% for 2024. The gross profit margin remains high at 100%, but negative EBIT and EBITDA margins indicate operational inefficiencies and high expenses relative to revenue.

Balance Sheet

The company maintains a strong equity base with a stockholders' equity of $1.02 billion, indicating solid foundational support. The debt-to-equity ratio is low at 0.02, suggesting minimal leverage which reduces financial risk. However, the equity ratio at 96.3% shows heavy reliance on equity financing. Return on equity is negative, reflecting ongoing losses.

Cash Flow

Operating cash flow is negative, showing the company is not generating cash from its core operations. Nevertheless, there was an improvement in free cash flow from -$52.43 million in 2023 to -$44.17 million in 2024, reflecting a positive growth rate in free cash flow. The financing cash flow remains strong due to significant cash inflows from financing activities.

Breakdown
TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
9.34M	10.59M	8.08M	8.61M	3.64M	0.00
	Gross Profit
8.83M	8.53M	6.13M	7.77M	3.52M	-13.00K
	EBIT
-113.58M	-98.85M	-72.98M	-67.09M	-32.93M	-4.84M
	EBITDA
-112.06M	-98.85M	-71.02M	-66.25M	-32.82M	-4.83M
	Net Income Common Stockholders
-77.74M	-68.99M	-58.29M	-54.15M	-32.56M	-5.25M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
1.01B	1.03B	344.03M	327.02M	374.96M	7.81M
	Total Assets
1.05B	1.06B	380.41M	364.01M	379.82M	16.22M
	Total Debt
22.61M	23.02M	24.54M	25.30M	194.00K	0.00
	Net Debt
-51.13M	-407.58M	5.34M	-26.12M	-35.39M	-7.81M
	Total Liabilities
38.30M	38.73M	36.06M	43.27M	13.50M	30.86M
	Stockholders Equity
1.01B	1.02B	344.35M	320.74M	366.33M	-14.64M
Cash Flow		Free Cash Flow
-46.53M	-44.17M	-52.42M	-49.37M	-18.46M	-4.37M
	Operating Cash Flow
-46.00M	-43.81M	-50.58M	-42.92M	-16.98M	-4.37M
	Investing Cash Flow
-484.68M	-258.02M	-41.19M	58.27M	-340.96M	0.00
	Financing Cash Flow
391.62M	713.24M	59.55M	500.00K	386.52M	11.52M

Janux Therapeutics Inc Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 23.61
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JANX, the sentiment is Negative. The current price of 23.61 is below the 20-day moving average (MA) of 24.94, below the 50-day MA of 26.86, and below the 200-day MA of 40.71, indicating a bearish trend. The MACD of -0.52 indicates Negative momentum. The RSI at 39.28 is Neutral, neither overbought nor oversold. The STOCH value of 24.57 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JANX.

Janux Therapeutics Inc Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
KYMR	61 Neutral	$3.05B	―	-32.17%	―	-25.85%	-23.89%
AGIO	61 Neutral	$1.99B	3.04	60.26%	―	25.96%	―
Sector *	54 Neutral	$5.34B	3.27	-45.10%	3.30%	16.80%	0.02%
RXRX	52 Neutral	$2.03B	―	-86.10%	―	29.32%	-11.00%
JANX	46 Neutral	$1.47B	―	-9.32%	―	28.12%	-11.01%
BEAM	45 Neutral	$1.72B	―	-38.04%	―	-82.38%	-164.76%
IRON	43 Neutral	$1.80B	―	-23.34%	―	―	-14.19%

Janux Therapeutics Inc Corporate Events

Janux Therapeutics Holds 2025 Annual Stockholders Meeting

On June 11, 2025, Janux Therapeutics, Inc. held its 2025 Annual Meeting of Stockholders, with 56,239,312 shares represented. During the meeting, stockholders elected three Class I directors to serve until the 2028 Annual Meeting, ratified Ernst & Young LLP as the independent accounting firm for 2025, approved executive compensation, and decided on the frequency of future advisory votes on executive compensation.

The most recent analyst rating on (JANX) stock is a Buy with a $25.00 price target. To see the full list of analyst forecasts on Janux Therapeutics Inc stock, see the JANX Stock Forecast page.